Unit dose pharmaceutical of a dry powder of one or more glucocorticoid or mineralocorticoid fludrocortisone acetate and/or triamcinolone acetonide comprised in a syringe

Abstract

A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

1 . A medical device comprising a unit dose pharmaceutical composition, the unit dose comprising:
 2.0 to 8.0 mg of a dry powder of fludrocortisone acetate and/or triamcinolone acetonide; wherein the unit dose pharmaceutical composition is comprised in a syringe.   
     
     
         2 . The medical device of  claim 1  for use or when used in the treatment of an eye disease or condition or predisposition thereto. 
     
     
         3 . The medical device of  claim 1  wherein no increase in intraocular pressure occurs as a result of injection of the unit dose pharmaceutical composition. 
     
     
         4 . The medical device of  claim 1  wherein intraocular pressure is maintained after injection of the unit dose pharmaceutical composition. 
     
     
         5 . A method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof, the method including injecting into the eye a unit dose pharmaceutical composition, the unit dose pharmaceutical composition comprising:
 2.0 to 8.0 mg of a dry powder of fludrocortisone acetate and/or triamcinolone acetonide; wherein the unit dose pharmaceutical composition is comprised in a syringe.   
     
     
         6 . The method of  claim 5 , wherein the injection comprises intravitreal and/or suprachoroidal injection. 
     
     
         7 . The method of  claim 5 , wherein the injection uses a double-barrelled syringe and the first barrel and a second barrel are injected substantially simultaneously. 
     
     
         8 . The method of  claim 5  wherein no increase in intraocular pressure occurs as a result of injection of the unit dose pharmaceutical composition. 
     
     
         9 . The method of  claim 5  wherein intraocular pressure is maintained after injection of the unit dose pharmaceutical composition.